Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Long-Term Debt Repayments (2020 - 2022)

Insight Molecular Diagnostics (IMDX) has disclosed Long-Term Debt Repayments for 3 consecutive years, with $575000.0 as the latest value for Q3 2022.

  • Quarterly Long-Term Debt Repayments rose 53.33% to $575000.0 in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2022, down 11.67% year-over-year, with the annual reading at $1.3 million for FY2022, 11.67% down from the prior year.
  • Long-Term Debt Repayments hit $575000.0 in Q3 2022 for Insight Molecular Diagnostics, up from $375000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $575000.0 in Q3 2022 to a low of $250000.0 in Q4 2020.
  • Historically, Long-Term Debt Repayments has averaged $384375.0 across 3 years, with a median of $375000.0 in 2021.
  • Biggest YoY gain for Long-Term Debt Repayments was 53.33% in 2022; the steepest drop was 0.0% in 2022.
  • Year by year, Long-Term Debt Repayments stood at $250000.0 in 2020, then skyrocketed by 50.0% to $375000.0 in 2021, then surged by 53.33% to $575000.0 in 2022.
  • Business Quant data shows Long-Term Debt Repayments for IMDX at $575000.0 in Q3 2022, $375000.0 in Q2 2022, and $375000.0 in Q1 2022.